TY - JOUR
T1 - Analysis of the fibrinogen and neutrophil-lymphocyte ratio in esophageal squamous cell carcinoma
AU - Arigami, Takaaki
AU - Okumura, Hiroshi
AU - Matsumoto, Masataka
AU - Uchikado, Yasuto
AU - Uenosono, Yoshikazu
AU - Kita, Yoshiaki
AU - Owaki, Tetsuhiro
AU - Mori, Shinichiro
AU - Kurahara, Hiroshi
AU - Kijima, Yuko
AU - Ishigami, Sumiya
AU - Natsugoe, Shoji
N1 - Publisher Copyright:
© 2015 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignancies in gastrointestinal tract cancers and even patients with early ESCC have a high metastatic potential. Difficulties are associated with clinically predicting tumor progression and prognosis based on conventional tumor markers determined from preoperative blood examinations. The aim of the present study was to measure plasma fibrinogen levels and the neutrophil-lymphocyte ratio (NLR) in blood and compare the clinical impacts of their combined values (fibrinogen and neutrophil-lymphocyte ratio score-F-NLR score) and the modified Glasgow Prognostic Score (mGPS) in patients with ESCC. We classified 238 patients with ESCC based on cut-off values for hyperfibrinogenemia (400 mg/dL) and high NLR (3.0) as F-NLR scores of 2 (both of these hematological abnormalities), 1 (one of these abnormalities), or 0 (neither abnormality). We also categorized patients based on cut-off values for high C-reactive protein (CRP) (0.5 mg/dL) and hypoalbuminemia (3.8 g/dL) as mGPS of 2 (elevated CRP and hypoalbuminemia), 1 (either elevated CRP or hypoalbuminemia), or 0 (neither elevated CRP nor hypoalbuminemia). The F-NLR score correlated with the depth of tumor invasion, lymph node metastasis, lymphovascular invasion, tumor size, and stage (all P0.05). Prognoses among the groups based on the F-NLR score and mGPS significantly differed (all P0.001). A multivariate analysis identified the depth of tumor invasion, lymph node metastasis, and FNLR score as independent prognostic factors (P=0.002, P=0.007, and P=0.037, respectively). The results of the present study showed that the F-NLR score is a promising blood predictor for tumor progression and outcomes in patients with ESCC.
AB - Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignancies in gastrointestinal tract cancers and even patients with early ESCC have a high metastatic potential. Difficulties are associated with clinically predicting tumor progression and prognosis based on conventional tumor markers determined from preoperative blood examinations. The aim of the present study was to measure plasma fibrinogen levels and the neutrophil-lymphocyte ratio (NLR) in blood and compare the clinical impacts of their combined values (fibrinogen and neutrophil-lymphocyte ratio score-F-NLR score) and the modified Glasgow Prognostic Score (mGPS) in patients with ESCC. We classified 238 patients with ESCC based on cut-off values for hyperfibrinogenemia (400 mg/dL) and high NLR (3.0) as F-NLR scores of 2 (both of these hematological abnormalities), 1 (one of these abnormalities), or 0 (neither abnormality). We also categorized patients based on cut-off values for high C-reactive protein (CRP) (0.5 mg/dL) and hypoalbuminemia (3.8 g/dL) as mGPS of 2 (elevated CRP and hypoalbuminemia), 1 (either elevated CRP or hypoalbuminemia), or 0 (neither elevated CRP nor hypoalbuminemia). The F-NLR score correlated with the depth of tumor invasion, lymph node metastasis, lymphovascular invasion, tumor size, and stage (all P0.05). Prognoses among the groups based on the F-NLR score and mGPS significantly differed (all P0.001). A multivariate analysis identified the depth of tumor invasion, lymph node metastasis, and FNLR score as independent prognostic factors (P=0.002, P=0.007, and P=0.037, respectively). The results of the present study showed that the F-NLR score is a promising blood predictor for tumor progression and outcomes in patients with ESCC.
UR - http://www.scopus.com/inward/record.url?scp=84947922810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947922810&partnerID=8YFLogxK
U2 - 10.1097/MD.0000000000001702
DO - 10.1097/MD.0000000000001702
M3 - Article
C2 - 26496280
AN - SCOPUS:84947922810
SN - 0025-7974
VL - 94
SP - e1702
JO - Medicine (United States)
JF - Medicine (United States)
IS - 42
ER -